ଫୁସଫୁସ କ୍ୟାନ୍ସର
First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor
କେଉଁଠିକୁ ଯିବେ
ଏହି trial ପାଇଁ ଭାରତରେ ୬ଟି hospital ରୋଗୀଙ୍କୁ ନେଉଛନ୍ତି.
ରେଜିଷ୍ଟ୍ରି ସାରାଂଶ (ଟେକ୍ନିକାଲ୍)
This is a phase 1, multicentre, first-in-human, open-label, dose-escalation/consolidation study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered JBI-778 in EGFR mutated lung cancer patients with or without brain metastasis, IDH mutated WHO grade 3 /4 recurrent glioma and ACC with evidence of recurrent, metastatic or advanced, incurable disease arising from any primary site. A total of 42 patients will be recruited in the study. The initial dose escalation up to cohort 3 (estimate to be 160mg) or until the pharmacologically active dose …
ସ୍ପୋନ୍ସର: ଜୁବିଲାଣ୍ଟ ଥେରାପ୍ୟୁଟିକ୍ସ ଇଣ୍ଡିଆ ଲିମିଟେଡ୍
ClinicalTrials.gov ରେ NCT07755397 · CTRI ନମ୍ବର CTRI/2024/07/070802
ରେଜିଷ୍ଟ୍ରିରେ ଶେଷ ଅପଡେଟ୍ 10 ଅଗଷ୍ଟ 2026 · ଆମେ 20 ଅକ୍ଟୋବର 2026 ରେ ପଢିଲୁ